Shot chasers: big pharma’s covid-19 boost

The pandemic has caused a shift in how drug firms are viewed: their capacity for big-money innovation will give them immunity in the crisis. Widespread homeworking will have broad consequences, from commercial-property values to urban demographics. And a seemingly innocuous Hong Kong history exam is a window into the territory’s increasingly fraught politics. 

For full access to print, digital and audio editions of The Economist, subscribe here


See for privacy and opt-out information.